Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623JCT

PASSWORD:DDS44KNB

* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 11:11:31 ON 24 MAR 2006
FILE 'REGISTRY' ENTERED AT 11:11:31 ON 24 MAR 2006
COPYRIGHT (C) 2006 American Chemical Society (ACS)
ENTER LOGIC EXPRESSION OR (END):end

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\10776002 KINASE INHs.str



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
1-10 2-13 4-12 8-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
1-2 1-6 1-10 2-3 2-13 3-4 4-5 4-12 5-6 5-7 6-9 7-8 8-9 8-11 13-14
13-18 14-15 15-16 16-17 17-18

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
Generic attributes :
12:
Saturation : Unsaturated
Type of Ring System : Monocyclic

L4 STRUCTURE UPLOADED

=> que L4

L5 QUE L4

=> d l4
L4 HAS NO ANSWERS
L4 STR



OOPS, WRONG STRUCTURE. THIS IS A PYRROLO[1,2-a]PYRAZINE, NOT AN IMIDAZO[1,2-a]PYRAZINE.

G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 11:14:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2735 TO ITERATE

73.1% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 51564 TO 57836
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 11:14:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 55616 TO ITERATE

100.0% PROCESSED 55616 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L7 2 SEA SSS FUL L4

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 173.98 TOTAL SESSION 180.79

FULL ESTIMATED COST

STN SEARCH TRANSCRIPT

10/776,631

[redacted]

```
FILE 'CAPLUS' ENTERED AT 11:14:46 ON 24 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 24 Mar 2006  VOL 144 ISS 14
FILE LAST UPDATED: 23 Mar 2006  (20060323/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7
L8            2 L7

=> d l-2 ibib abs

L8   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1971:125628  CAPLUS
DOCUMENT NUMBER:          74:125628
TITLE:                    New method for synthesizing pyrrolo[1,2-a]pyrazines
                          and pyrrolo[1,2-a]quinoxalines
AUTHOR(S):                Shvedov, V. I.; Altukhova, L. B.; Grinev, A. N.
CORPORATE SOURCE:         Vses. Nauchno-Issled. Khim.-Farm. Inst. im.
                          Ordzhonikidze, Moscow, USSR
SOURCE:                   Khimiya Geterotsiklicheskikh Soedinenii (1970), (8),
                          1048-50
                          CODEN: KGSSAQ; ISSN: 0132-6244
DOCUMENT TYPE:            Journal
LANGUAGE:                 Russian
GI    For diagram(s), see printed CA Issue.
AB    Alkylation of Na derivs. of 2-acylpyrroles with acetals of α-bromo
      carbonyl compds., followed by reaction with NH4OAc in HOAc gave
      pyrrolo[1,2-a]pyrazines (I).  Thus, 19 g 2-formylpyrrole in dioxane was
      treated with alc. NaOEt and then with 50.6 g BrCH2CH(OBu)2 in DMF.  The
      product was refluxed with 150 g NH4OAc in HAOc to give 8 g I (R = R1 = R2
      = R3 = R4 = H).  The following I were prepared (R, R1, R2, R3, and R4
      given):  H, Me, CO2Et, Me, Me; H, H, H, H, Ph; Ph, H, H, H, Ph.
      Similarly, alkylation of 8.5 g 2-benzoylpyrrole with 11.2 g
      α-bromocyclohexanone dimethyl ketal, followed by heating with 40 g
      NH4OAc, gave 7 g IV, which was refluxed with Ni in xylene-to give 96% V.

L8   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1969:413142  CAPLUS
DOCUMENT NUMBER:          71:13142
TITLE:                    Derivative of pyrrolo[1,2-a]pyrazine
INVENTOR(S):              Shvedov, V. I.; Altukhova, L. B.; Bocharnikova, A. V.;
                          Grinev, A. N.
PATENT ASSIGNEE(S):       Ordzhonikidze, S., All-Union Scientific-Research
                          Chemical-Pharmaceutical Institute
SOURCE:                   U.S.S.R.  From: Otkrytiya, Izobret., Prom. Obraztsy,
                          Tovarnye Znaki 1969, 46(8), 22.
                          CODEN: URXXAF
DOCUMENT TYPE:            Patent
LANGUAGE:                 Russian
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ----------          ----   --------    -------------------      --------
     SU 237153                  19690212    SU                       19671201
GI   For diagram(s), see printed CA Issue.
AB   The title compound (I, R1, R2, R3, R4, and R5 = H, and alkyl, or an aryl) is
     prepared by reacting the Na derivative of 2-acylpyrrole with an
     α-bromocarbonyl compound or its acetal.  The dicarbonyl derivative
     obtained is treated with NH4OAc in boiling HOAc.


=> d l-2 hitstr
'L-2' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
```

structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d 1-2 hitstr

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
IT **24608-67-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24608-67-1 CAPLUS
CN Pyrrolo[1,2-a]pyrazine, 1,3-diphenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
IT **24608-67-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24608-67-1 CAPLUS
CN Pyrrolo[1,2-a]pyrazine, 1,3-diphenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)



● HCl

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	11.14	191.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

FILE 'REGISTRY' ENTERED AT 11:16:02 ON 24 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAR 2006 HIGHEST RN 877759-05-2
DICTIONARY FILE UPDATES: 22 MAR 2006 HIGHEST RN 877759-05-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from  *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\10776002 KINASE INHs.str






```
chain nodes :
10  11  12
ring nodes :
1  2  3  4  5  6  7  8  9  13  14  15  16  17  18
chain bonds :
1-10  2-13  4-12  8-11
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  13-14  13-18  14-15  15-16  16-17
 17-18
exact/norm bonds :
1-2  1-6  1-10  2-3  2-13  3-4  4-5  4-12  5-6  5-7  6-9  7-8  8-9  8-11  13-14
13-18  14-15  15-16  16-17  17-18


G1:C,N

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom
Generic attributes :
12:
Saturation              : Unsaturated
Type of Ring System     : Monocyclic



L9      STRUCTURE UPLOADED

=> que L9

L10  QUE L9

=> d 19
L9 HAS NO ANSWERS
L9              STR
```

MONOCYCLIC, UNSATURATED, Het OR CARBO -

CORRECT STRUCTURE




```
G1 C,N


Structure attributes must be viewed using STN Express query preparation.


=> s 19
SAMPLE SEARCH INITIATED 11:16:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      637 TO ITERATE

100.0% PROCESSED      637 ITERATIONS                                  5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        11226 TO    14254
PROJECTED ANSWERS:               5 TO      234

L11           5 SEA SSS SAM L9

=> s 19 sss full
FULL SEARCH INITIATED 11:16:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    12382 TO ITERATE

100.0% PROCESSED    12382 ITERATIONS                                 77 ANSWERS
SEARCH TIME: 00.00.01

L12          77 SEA SSS FUL L9

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  166.94     358.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -1.50

FILE 'CAPLUS' ENTERED AT 11:16:32 ON 24 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
```

FILE COVERS 1907 - 24 Mar 2006 VOL 144 ISS 14
FILE LAST UPDATED: 23 Mar 2006 (20060323/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l12
L13 3 L12

=> d l-3 ibib abs hitstr

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:295613 CAPLUS
DOCUMENT NUMBER: 142:482014
TITLE: Synthesis of some 6,8-diarylimidazo[1,2-a]pyrazine derivatives by using either reflux or microwave irradiation method and investigation of their anticancer activities
AUTHOR(S): Demirayak, Seref; Kayagil, Ismail
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, 26470, Turk.
SOURCE: Journal of Heterocyclic Chemistry (2005), 42(2), 319-325
CODEN: JHTCAD; ISSN: 0022-152X
PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:482014
GI



I



II

AB The preparation of 6,8-diarylimidazo[1,2-a]pyrazines, e.g. I, via the reaction of 1-(2-aryl-2-oxoethyl)-2-aryloylimidazole derivs., e.g. II, with ammonium acetate in acetic acid utilizing a new method, is reported. Anticancer activities of the compds. obtained were evaluated and the activity values were reported.

IT 852101-80-5P 852101-81-6P 852101-84-9P
852101-85-0P 852101-86-1P 852101-87-2P
852101-89-4P 852101-90-7P 852101-91-8P
852101-92-9P 852101-93-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of some 6,8-diarylimidazo[1,2-a]pyrazine derivs. by using either reflux or microwave irradiation method and investigation of their anticancer activities)

RN 852101-80-5 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-(4-methoxyphenyl)-8-phenyl- (9CI) (CA INDEX NAME)



RN 852101-81-6 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-(4-chlorophenyl)-8-phenyl- (9CI) (CA INDEX NAME)



RN 852101-84-9 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-(4-methoxyphenyl)-8-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 852101-85-0 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-(4-chlorophenyl)-8-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 852101-86-1 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 852101-87-2 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-methoxyphenyl)-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 852101-89-4 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-(4-chlorophenyl)-8-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 852101-90-7 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-chlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 852101-91-8 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-chlorophenyl)-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 852101-92-9 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-chlorophenyl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 852101-93-0 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6,8-bis(4-chlorophenyl)- (9CI) (CA INDEX NAME)



IT 852101-63-4P 852101-79-2P 852101-82-7P
852101-83-8P 852101-88-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of some 6,8-diarylimidazo[1,2-a]pyrazine derivs. by using either reflux or microwave irradiation method and investigation of their anticancer activities)

RN 852101-63-4 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6,8-diphenyl- (9CI) (CA INDEX NAME)



RN 852101-79-2 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-(4-methylphenyl)-8-phenyl- (9CI) (CA INDEX NAME)



RN 852101-82-7 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-methylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 852101-83-8 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6,8-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 852101-88-3 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6,8-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:696382 CAPLUS
DOCUMENT NUMBER: 141:225538
TITLE: Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity, particularly EphB4 kinase, and their preparation, pharmaceutical compositions, and methods of use for modulation and

APPLICANTS

treatment of diseases and disorders

INVENTOR(S): Currie, Kevin S.; Desimone, Robert W.; Pippin, Douglas A.; Darrow, James W.; Mitchell, Scott A.

PATENT ASSIGNEE(S): Cellular Genomics, Inc., USA

SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072081	A1	20040826	WO 2004-US3923	20040210
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005054648	A1	20050310	US 2004-776002	20040210
US 2005054649	A1	20050310	US 2004-776631	20040210

PRIORITY APPLN. INFO.: US 2003-446379P P 20030210

OTHER SOURCE(S): MARPAT 141:225538

GI

APPLICANTS



I

II

AB The invention pertains to compds. I and all pharmaceutically acceptable forms thereof [wherein: R1 = pyridyl or pyrimidinyl (un)substituted with 0-3 selected substituents; W = Ph or 5- or 6-membered N/O/S heteroaryl with 1-4 heteroatoms and 0-3 selected substituents; X = N or CH; R2 = (alkoxy)alkyl, (hetero)cycloalkyl(alkyl), (alkoxy)alkoxy; or R2 = phenyl(alkyl) or heteroaryl(alkyl) bearing 0-3 selected substituents; Z = (CR8R9)n, CONR10, NR10CO, or NR10CONR11; R8, R9 = H, alkyl, alkoxy, halo; n = 0-2; R10, R11 = H, alkyl, or Ph or heteroaryl with 0-3 selected substituents; R3 = H, alkyl; or R3 = (hetero)cycloalkyl(alkyl), Ph, or heteroaryl each bearing 0-3 selected substituents; or R3 = phenoxyphenyl with each ring bearing 0-3 selected substituents). Addnl. compds. with a linker group between R1 and W are disclosed but neither claimed nor prepared The compds. are modulators of kinase activity and Hsp90 complex activity. In particular, they are highly active inhibitors of angiogenic and oncogenic kinases. The invention also provides pharmaceutical comps. containing one or more compound I, or a pharmaceutically acceptable form of such compds., and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including breast neoplasms, endometrial cancer, colon cancer, and neck squamous cell carcinoma. The methods of treatment include administering a sufficient amount of I or a salt to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to EphB4 modulation. Methods of treatment include administering I as a single active agent or administering a compound I in combination with one or more other therapeutic agents. The invention also includes a method for determining the presence of EphB4 kinase in a sample, comprising contacting the sample with a compound I, or form thereof, and detecting the amount of compound or form bound to EphB4 kinase, and therefrom determining the presence or absence of EphB4 kinase in the sample. Ten compds. I were prepared in examples. For instance, compound II was prepared in 4 steps: (1) deprotection of BrCH2CH(OMe)2 with HBr and cyclocondensation with 3,5-dibromo-2-aminopyrazine to give 6,8-dibromoimidazo[1,2-a]pyrazine; (2) aminolysis of the 8-bromo with 4-(1H-imidazol-2-yl)pyridine; (3) Suzuki coupling of the 6-bromo with 3-H2NC6H4B(OH)2.HCl; and (4) carbamoylation of the amino group with 2-isocyanato-1-methoxy-4-(trifluoromethyl)benzene. In an assay for EphB4 kinase activity, using human recombinant EphB4 kinase cytoplasmic domain (Genbank Accession Number AY056047), compds. I had IC50 values of 10 μM or less, with some particularly preferred compds. having values of 100 nM or less. Similar inhibitory potencies were found against VEGF-R2, c-Kit, and Tie-2 kinases in vitro.

IT **746642-12-6P**, 1-(2-Methoxy-5-trifluoromethylphenyl)-3-[3-[8-[2-(pyridin-4-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
746642-13-7P, 1-(4-Methoxy-3-trifluoromethylphenyl)-3-[3-[8-[2-(pyridin-4-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
746642-14-8P, 1-(2-Methoxy-5-trifluoromethylphenyl)-3-[3-[8-[2-(pyridin-3-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
746642-15-9P, 1-(5-Chloro-2-methoxyphenyl)-3-[3-[8-[2-(pyridin-4-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
746642-16-0P, 1-(5-Fluoro-2-trifluoromethylphenyl)-3-[3-[8-[2-(pyridin-4-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
746642-17-1P, 1-(5-Chloro-2-trifluoromethylphenyl)-3-[3-[8-[2-(pyridin-4-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
746642-18-2P, 1-[5-Chloro-2,4-di(methyloxy)phenyl]-3-[3-[8-[2-(pyridin-4-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
746642-19-3P, 1-(4-Methyl-3-trifluoromethylphenyl)-3-[3-[8-[2-(pyridin-4-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
746642-20-6P, 1-(4-Chloro-3-trifluoromethylphenyl)-3-[3-[8-[2-(pyridin-4-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
746642-21-7P, 1-(2-Methoxy-5-trifluoromethylphenyl)-3-[3-[8-[3-(pyridin-4-yl)pyrazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroarylphenylimidazopyrazines as kinase modulators for treatment of cancer and angiogenesis)

RN 746642-12-6 CAPLUS

CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[3-[8-[2-(4-pyridinyl)-1H-

imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-13-7 CAPLUS
CN Urea, N-[4-methoxy-3-(trifluoromethyl)phenyl]-N'-[3-[8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-14-8 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[3-[8-[2-(3-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-15-9 CAPLUS
CN Urea, N-(5-chloro-2-methoxyphenyl)-N'-[3-[8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-16-0 CAPLUS
CN Urea, N-[5-fluoro-2-(trifluoromethyl)phenyl]-N'-[3-[8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-17-1 CAPLUS
CN Urea, N-[5-chloro-2-(trifluoromethyl)phenyl]-N'-[3-[8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-18-2 CAPLUS
CN Urea, N-(5-chloro-2,4-dimethoxyphenyl)-N'-[3-[8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-19-3 CAPLUS
CN Urea, N-[4-methyl-3-(trifluoromethyl)phenyl]-N'-[3-[8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-20-6 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-[8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-21-7 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[3-[8-[3-(4-pyridinyl)-1H-pyrazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



IT 746642-23-9P, 3-[8-[2-(Pyridin-4-yl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenylamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heteroarylphenylimidazopyrazines as kinase modulators for treatment of cancer and angiogenesis)
RN 746642-23-9 CAPLUS
CN Benzenamine, 3-[8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:696381 CAPLUS
DOCUMENT NUMBER: 141:225537
TITLE: Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity and their preparation, pharmaceutical compositions, and methods of use
INVENTOR(S): Currie, Kevin S.; Desimone, Robert W.; Pippin, Douglas A.; Darrow, James W.; Mitchell, Scott A.
PATENT ASSIGNEE(S): Cellular Genomics, Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072080	A1	20040826	WO 2004-US3922	20040210
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,				

BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,
CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,
ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,
IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,
LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,
MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

US 2005054648 A1 20050310 US 2004-776002 20040210
US 2005054649 A1 20050310 US 2004-776631 20040210
PRIORITY APPLN. INFO.: US 2003-446379P P 20030210
OTHER SOURCE(S): MARPAT 141:225537
GI



I II

AB The invention pertains to compds. I and all pharmaceutically acceptable forms thereof [wherein: R1 = H, halo, alkyl, alkoxy, (hetero)cycloalkyl(alkyl), sulfonamide, alkoxyalkyl, alkoxyalkoxy, (di)alkylamino(alkyl); or R1 = Ph or a benzo-fused 5- to 7-membered N/O/S heterocycloalkyl bearing 0-3 selected substituents; W = Ph or 5- or 6-membered N/O/S heteroaryl with 1-4 heteroatoms and 0-3 selected substituents; X = N or CH; R2 = (alkoxy)alkyl, (hetero)cycloalkyl(alkyl), (alkoxy)alkoxy; or R2 = phenyl(alkyl) or heteroaryl(alkyl) bearing 0-3 selected substituents; Z = (CR8R9)n, CONR10, NR10CO, or NR10CONR11; R8, R9 = H, alkyl, alkoxy, halo; n = 0-2; R10, R11 = H, alkyl, or Ph or heteroaryl with 0-3 selected substituents; R3 = H, alkyl; or R3 = (hetero)cycloalkyl(alkyl), Ph, or heteroaryl each bearing 0-3 selected substituents; or R3 = phenoxyphenyl with each ring bearing 0-3 selected substituents]. Addnl. compds. with a linking group between R1 and W are disclosed but neither prepared nor claimed. The compds. I are modulators of kinase activity and Hsp90 complex activity. Certain compds. I are highly active inhibitors of Hsp90 complex activity. The invention also provides pharmaceutical compns. containing one or more compound I, or a pharmaceutically acceptable form of such compds., and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases. The methods of treatment include administering a sufficient amount of a compound I or a form thereof to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating non-human patients, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to Hsp90 complex modulation. Methods of treatment include administering a compound I as a single active agent or administering a compound I in combination with one or more other therapeutic agents. The invention also includes a method for determining the presence of certain kinases or Hsp90 complex in a sample, comprising contacting the sample with a compound I, or form thereof, and detecting Hsp90 complex activity in the sample. Almost 50 compds. I were prepared in examples. For instance, compound II was prepared in 4 steps: (1) deprotection of BrCH2CH(OEt)2 with HBr and cyclocondensation with 3,5-dibromo-2-aminopyrazine to give 6,8-dibromoimidazo[1,2-a]pyrazine; (2) aminolysis of the 8-bromo with 4-(p-tolyl)-1H-imidazole; (3) Suzuki coupling of the 6-bromo with 3-H2NC6H4B(OH)2.HCl; and (4) carbamoylation of the amino group with 1-isocyanato-2-methylbenzene. In a tumor cell monolayer proliferation assay using MCF-7 or HCT-15 cells, compds. I had IC50 values of 25 μM or less, with certain compds. having values of 10 μM or less.

IT **746653-81-6P**, 1-[3-[8-(4-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea **746653-82-7P**, 1-(4-Chlorophenyl)-3-[3-[8-(4-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-83-8P**, 1-(2-Methylsulfanylphenyl)-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-84-9P**, 1-[3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea **746653-85-0P**, 1-(4-Chlorophenyl)-3-[3-[8-[4-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-86-1P**, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea **746653-87-2P**, 1-(4-Chlorophenyl)-3-[3-[8-(4-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-88-3P**, 1-o-Tolyl-3-[3-[8-(4-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-89-4P**, 1-(4-Chlorophenyl)-3-[3-[8-(4-methylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-90-7P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[4-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-91-8P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(4-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-92-9P**, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]urea **746653-93-0P**, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(morpholin-4-yl)methyl]phenyl]urea **746653-94-1P**, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[[(3-ethoxypropyl)amino]methyl]phenyl]urea **746653-95-2P**, 1-(4-Chlorophenyl)-3-[3-[8-(3-phenylpyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-96-3P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(3-phenylpyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-97-4P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-98-5P**, 4-Chloro-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746653-99-6P**, 3-[(Morpholin-4-yl)methyl]-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-00-2P**, 4-[(Morpholin-4-yl)methyl]-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-01-3P**,

1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-02-4P, 1-[3-[8-(2-p-Tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 746654-03-5P, 1-[4-[(Morpholin-4-yl)methyl]phenyl]-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-04-6P, 6-[4-[(Morpholin-4-yl)methyl]phenyl]-8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazine 746654-05-7P, 1-(4-Chlorophenyl)-3-[3-[8-(2-o-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-06-8P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-o-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-07-9P, 1-(4-Chlorophenyl)-3-[3-[8-[2-(2-methoxyphenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-08-0P, 1-(4-Chlorophenyl)-3-[3-[8-[2-(2-fluorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-09-1P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[2-(2-fluorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-10-4P, 1-[3-[8-[2-(2-Fluorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 746654-11-5P, 1-[3-[8-[2-(2-Methoxyphenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 746654-12-6P, 1-(4-Chlorophenyl)-3-[3-[8-(2-isopropylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-13-7P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-isopropylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-14-8P, 1-[3-[8-(4-Bromoimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 746654-15-9P, 4-Fluoro-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-16-0P, 3-Methoxy-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-17-1P, 3-Methoxy-4-methyl-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-18-2P, N-[3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-19-3P, 2,6-Dimethyl-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-20-6P, 4-Fluoro-N-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-21-7P, 3-Methoxy-N-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-22-8P, 3-Methoxy-4-methyl-N-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-23-9P, 2-(4-Chlorophenyl)-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide 746654-24-0P, 2-(4-Chlorophenyl)-N-[3-[8-[2-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide 746654-25-1P, N-[3-[8-[2-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-2-(3-trifluoromethylphenyl)acetamide 746654-26-2P, 1-[3-[8-[2-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(morpholin-4-yl)methyl]phenyl]urea 746654-27-3P, 1-(4-Chlorobenzyl)-3-[3-[8-[2-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-28-4P, 1-[3-[8-[2-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-(4-methylpiperazin-1-ylmethyl)phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)

RN 746653-81-6 CAPLUS
CN Urea, N-(2-methylphenyl)-N'-[3-[8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-82-7 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-83-8 CAPLUS
CN Urea, N-[2-(methylthio)phenyl]-N'-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-84-9 CAPLUS
CN Urea, N-(2-methylphenyl)-N'-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-85-0 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-86-1 CAPLUS
CN Urea, N-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 746653-87-2 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[4-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-88-3 CAPLUS
CN Urea, N-(2-methylphenyl)-N'-[3-[8-[4-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-89-4 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(4-methyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-90-7 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-91-8 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-92-9 CAPLUS
CN Urea, N-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-93-0 CAPLUS
CN Urea, N-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 746653-94-1 CAPLUS
CN Urea, N-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-[[(3-ethoxypropyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-95-2 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(3-phenyl-1H-pyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-96-3 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-(3-phenyl-1H-pyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-97-4 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-98-5 CAPLUS
CN Benzamide, 4-chloro-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-99-6 CAPLUS
CN Benzamide, 3-(4-morpholinylmethyl)-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-00-2 CAPLUS
CN Benzamide, 4-(4-morpholinylmethyl)-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-01-3 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-02-4 CAPLUS
CN Urea, N-(3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 746654-03-5 CAPLUS
CN Urea, N-[4-(4-morpholinylmethyl)phenyl]-N'-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-04-6 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-[4-(4-morpholinylmethyl)phenyl]-8-(2-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 746654-05-7 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[2-(2-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-06-8 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[2-(2-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-07-9 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[2-(2-methoxyphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-08-0 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[2-(2-fluorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-09-1 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[2-(2-fluorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-10-4 CAPLUS
CN Urea, N-[3-[8-[2-(2-fluorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 746654-11-5 CAPLUS
CN Urea, N-[3-[8-[2-(2-methoxyphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 746654-12-6 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[2-(1-methylethyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-13-7 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[2-(1-methylethyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-14-8 CAPLUS
CN Urea, N-[3-[8-(4-bromo-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 746654-15-9 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-16-0 CAPLUS
CN Benzamide, 3-methoxy-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-17-1 CAPLUS
CN Benzamide, 3-methoxy-4-methyl-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-18-2 CAPLUS
CN Benzamide, N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-19-3 CAPLUS
CN Benzamide, 2,6-dimethyl-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-20-6 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-21-7 CAPLUS
CN Benzamide, 3-methoxy-N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-22-8 CAPLUS
CN Benzamide, 3-methoxy-4-methyl-N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-23-9 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-24-0 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-25-1 CAPLUS
CN Benzeneacetamide, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 746654-26-2 CAPLUS
CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 746654-27-3 CAPLUS
CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 746654-28-4 CAPLUS

CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



IT 746654-30-8P, 3-[8-(4-p-Tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)
RN 746654-30-8 CAPLUS
CN Benzenamine, 3-[8-[4-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]- (9CI) (CA INDEX NAME)



IT 746654-31-9, 3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)
RN 746654-31-9 CAPLUS
CN Benzenamine, 3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]- (9CI) (CA INDEX NAME)



=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.01	377.88
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-3.75

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:21:08 ON 24 MAR 2006